NAi performs comprehensive multi-omics analysis on unbiased, and clinically annotated patient samples from our industry leading proprietary biobank. The rich multi-omics data is then fed into our Bayesian causal AI models run on Frontier, one of the world’s fastest supercomputers. This approach has led to five phase II/III ready drug candidates and over a hundred targets and biomarkers discovered.

NAi discoveries have consistently led to successful clinical trials.

AI Drug Discovery

BPGbio’s Protein Homeostasis program is built around a First-In-Class ubiquitin conjugating enzyme (E2) based targeted protein degradation (TPD) platform (“E2 Platform”).

Protein Homeostasis

Clinical trials are where innovation meets verification. The progress BPGbio is making in clinical trials represents the strongest testament to the efficacy of our AI-powered drug discovery platform – the NAi Interrogative Biology® platform.

Primary CoQ10 Deficiency  Glioblastoma (GBM)  Pancreatic Cancer  Epidermolysis Bullosa (EB)  Sarcopenia  

As a biotech company, BPGbio’s mission is to deliver more optimized medicine for a healthier future. Harnessing unbiased data from our own biobank and leveraging purposely built AI, we are developing a range of transformative therapies aimed at addressing unmet medical needs.

Pipeline

We invite forward-thinking organizations to partner with us. Whether it’s licensing our assets or harnessing the power of NAi for new discovery, we’re committed to creating strong relationships that drive success.

Work With Us

With over 400 US and international patents, BPGbio’s intellectual property portfolio reinforces our leadership in bioscience, offering partners and investors a foundation of exclusivity and fostering revolutionary advancements in the healthcare landscape.

Explore Our Patents